gene therapy development

Genetic Medicines Inspired by Nature Revolutionizing Gene Therapy With Non-Viral Delivery Methods for Stargardt's, ALS, Alzheimer’s, Duchenne & other Systemic Diseases Learn How It Works Pioneering Non-Viral Gene Delivery At AAVINUE, we are driven by a vision to revolutionize gene therapy for debilitating diseases using our proprietary Mini-nucleosome non-viral delivery technology. Our work is dedicated to overcoming the challenges of viral vectors and LNPs to enable transformative therapies for conditions like ALS, Stargardt's, Alzheimer’s Disease, and other genetic diseases. Patient Focused Patient first mentality drives our entire drug development process. Cutting-Edge Technology Leader in non-viral gene Delivery and Cargo technologies. Robust Platforms Customizable for targeted delivery of DNA/RNA to treat diverse diseases Designed for Success Highly accessible to patients via.

non-viral gene deliverytargeted delivery of DNA/RNA

BioViva USA Inc is a research and development company working on medical technologies and treatments aimed at addressing aging-associated disorders and enhancing human health through genetic interventions. It develops gene therapy platforms, including AAV and CMV gene therapy, designed to help cells behave more youthfully and target the biological processes of aging. BioViva states it does not provide gene therapy to patients.

AAV-gene therapyCMV gene therapyresearch and development

Blackfin Bio is a UK-based biotechnology spinout company from the University of Sheffield, founded in November 2023, committed to developing next-generation gene therapies. Its mission is to bring hope, healing and life-changing benefits to patients living with rare and other diseases of the Central Nervous System, including SPG47. The company aims to accelerate the clinical development of gene therapies into life-changing treatments.

clinical developmenttranslational research

Couragene, Inc. is a company based at the New Jersey Bioscience Center in North Brunswick, NJ, focused on developing gene and biologic therapies through novel delivery platforms.

biologic therapy developmentnovel delivery platforms

Expression Therapeutics is a clinical-stage biotechnology company pioneering a curative stem cell therapy for hemophilia A and best-in-class cell therapies for neuroendocrine tumors (NETs). Its work is powered by proprietary AI-based technological breakthroughs and an integrated 43,000 sq ft GMP manufacturing facility in Cincinnati, Ohio.

cell therapy manufacturingGLP labsGMP manufacturinglentiviral vector engineeringmodular cleanrooms

IMPECCURE is an early-stage biotech company developing precise and innovative therapeutics for activity-dependent neurological disorders, including drug-resistant epilepsy and related conditions. Its novel active neuron tagging system enables highly accurate target discovery and gene therapy development tailored to dysfunctional neural circuits, with a focus on first-in-class solutions.

active neuron tagging systemtarget discovery

Jaya Biosciences is a privately held preclinical-stage life sciences company developing CNS-directed gene therapies for genetically defined neurodegenerative diseases, including Alzheimer's, Parkinson's, and frontotemporal dementia. Its lead therapy JB111 is an experimental CNS-directed AAV9-mediated PPT1 gene therapy being developed for Alzheimer's disease associated with PPT1 haploinsufficiency.

CNS-directed AAV9-mediated gene therapypreclinical drug development